Australia, Sept. 2 -- Maze Therapeutics Inc., owns the trademark (2557994) for 'MAZE' till April 21, 2035.
Status: protected:
Registered/protected
Classes: 1 [Diagnostic preparations for scientific or research use other than for medical use; assays and reagents for scientific or medical research use; genetic testing preparations for scientific or medical research use, namely, assays and reagents for use in genetic and biomedical research; cells for scientific or medical research use.], 5 [Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; pharmaceutical preparations for treating genetic diseases and disorders; pharmaceutical preparations for treating and lysosomal storage disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the reproductive system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases and disorders; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the prevention and treatment of obesity; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; reagents for medical use; genetic testing preparations for medical purposes, namely, medical diagnostic reagents and assays for testing of body fluids, cells, and tissue; cells for medical or clinical use; medical diagnostic and testing assays, namely, medical diagnostic reagents and assays for testing of body fluids, cells, and tissue.] and 42 [Pharmaceutical research and development services; research in the field of genetic modifiers and related therapeutics; research in the field of genetic variations linked to medical diseases or conditions; research in the field of variant functionalization.]
Type of Mark: Word
Date of Acceptance: June 25
Registration Advertised: Sept. 1
For further details contact Joyce Liou of Morrison & Foerster LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2557994.
Disclaimer: Curated by HT Syndication.
